Affiliation:
1. Mannheim Institute of Public Health, Social and Preventive Medicine,
University Medicine Mannheim, Heidelberg University
2. Department of Health Sciences, University of York
Abstract
Abstract
Aim Despite the growing number of elderly cancer patients, health economic
evaluations have not put enough attention on this patient group. We reflect on
the current state of health economic evaluations for geriatric patients and
present suggestions for improvements.
Method We reviewed the scientific literature on health economic
evaluations for geriatric patients in Germany and internationally. Additionally,
we conducted a scoping review on cost-utility analyses on cancer treatment for
older patients (> 60 years).
Results The literature review resulted in eight relevant studies. Besides
the paucity of economic evaluations for elderly patients, we also present
quality limitations. From the literature, we identify four recommendations
regarding cost calculation, geriatric assessment, patient decision-making and
quality of life on how to design better economic evaluations for geriatric
cancer treatment.
Conclusion The demographic change requires more attention regarding
elderly patients in health economics. Including patients above 70 years of age
in health economic evaluations and improving cost-utility analyses will help to
improve resource allocations and effective healthcare for the elderly.